Professor Johanna Olweus and her research team of 16 have received NOK 4.5 million in grants from the Danish Novo Nordisk Foundation. The money will be used to commercialize a whole new type of cancer immunotherapy that Olweus and her team are developing.
They have found a way to program cancer patients' immune cells to fight cancer using healthy human immune cells. This method allows the immune system to attack the cancer cells specifically, without harming other cells.
Published in Level 2 journals, first or last author from Oslo University Hospital.
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes
Lancet Diabetes Endocrinol, 10 (12), 840
Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression
J Immunol, 209 (10), 2042-2053
Use of antihypertensive drugs and risk of cutaneous melanoma: a nationwide nested case-control study
Int J Epidemiol (in press)